# ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

> **NCT00981617** · PHASE2 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 406 (actual)

## Conditions studied

- Alcohol Dependence

## Interventions

- **DRUG:** ALKS33 (RDC-0313) (1 mg)
- **DRUG:** ALKS33 (RDC-0313) (2.5 mg)
- **DRUG:** ALKS33 (RDC-0313) (10 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00981617
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2011-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981617, "ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00981617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*